Bora Pharmaceuticals announced plans for significant investments to expand its manufacturing and packaging capabilities at its facility in Maple Grove, Minnesota. This is a major upgrade to the site, which Bora acquired in 2024 as part of its $210 million acquisition of Upsher-Smith Laboratories, expanding its U.S. manufacturing footprint.
“With pharmaceutical companies relying more heavily on specialized CDMO partners to scale production and maintain quality, top-tier manufacturing capacity and technical expertise are at a premium,” said J.D. Mowery, president of Bora’s CDMO business. “Bora’s Maple Grove facility offers a unique opportunity for innovators to secure space in a state-of-the-art site staffed by experts in formulation development, tech transfer, and commercial manufacturing.”
The first phase of Bora’s investment will add a Gerteis Macro-Pactor® at the company’s state-of-the-art site. This investment initiates a broader buildout of 100,000 square feet of dedicated shell space designed to streamline production for partners with high-volume needs.
The Gerteis Macro-Pactor® roller compactor will be installed and operational in the third quarter of 2025.
“As we complete our transition from Upsher-Smith, we’re creating the infrastructure to deliver integrated manufacturing, packaging, and analytical services with the speed and quality our clients need,” shared Dennis Hall, Vice President and General Manager of the Maple Grove site. “As we expand our capabilities, we look forward to tapping into all the experience and talent in the area.”
The facility offers on-site quality control laboratories and a dedicated development team to support product and analytical development as well as innovation. It is an FDA-inspected manufacturing site and meets global health authority requirements, ensuring regulatory compliance.